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Background: Opioids have, at most, small benefits for non-cancer pain in the medium and long-term but there
is good evidence that they cause harm. The current study describes the characteristics and clinical status of
people taking regular opioids in Great Britain and determines whether use is associated with mortality risk.
Methods: An analysis of participants in UK Biobank, a prospective population-based study. At recruitment
(200610) participants reported medicines which they regularly used in addition to lifestyle and health-
related factors. Information was available on deaths until October 2016.
Findings: There were 466 486 participants (54% women) aged 4069 years and without a prior history of can-
cer of whom 5.5% were regularly using opioids. Use increased with age-group, was more common in females
(6.3% v. 4.6%) and 87% of persons using them reported chronic pain. The highest rates of use (~1 in 9) were in
people with low household income, who left school <16 years and lived in areas with high deprivation.
Amongst 15,032 people who could not work because of ill-health, 1 in 3 were regularly taking opioids. Regu-
lar users reported insomnia (88.7%), a recent major recent life event (57.3%) and were much more likely than
non-users to rate their health as poor (RR 5.5, 99% CI (4.9, 6.1)). Those taking weak (4.2% of participants) or
strong (1.4%) opioids were more likely to die during follow-up (6.9% and 9.1% respectively v. 3.3% in non-
users) an excess which remained after adjustment for demographic, socio-economic, health and lifestyle fac-
tors (MRR 1.18 99% CI (1.06, 1.32) and 1.20 99% CI (1.01, 1.43)) respectively.
Interpretation: Regular use of opioids is common in Great Britain, particularly in groups of low socio-eco-
nomic status. Most users still report chronic pain, poor health generally and are at increased risk of prema-
ture death although it is not established that this relationship is causal.
Funding: There were no external sources of funding obtained for the current analyses.
© 2020 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license.
(http://creativecommons.org/licenses/by-nc-nd/4.0/)Keywords:
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Chronic pain is an important public health problem  around 2 in
10 of the general population sample reported persistent and intense
pain in one pan-European study [1] while a meta-analysis of epide-
miological studies conducted world-wide found that 3 in 10 persons
had chronic pain [2]. The aetiology of chronic pain is multifactorial
and complex, with onset of pain often in early adulthood. Long-term
prospective studies demonstrate an increased risk related to adverse
social environment in early life, as well as physically and emotionally
traumatic events [36]. A review of factors which predict an episode
of pain becoming chronic, and causing long-term disability, found
the strongest evidence in relation to clinical factors (disabling, persis-
tent and multi-site pain), older age, and mood [7]. A consequence ofchronic pain is an increased risk of death [8]. Data from UK Biobank
has shown, specifically, that persons with chronic widespread pain
(CWP) have a markedly increased risk of dying during follow-up
(mortality risk ratio (MRR) 2.43, 99%CI 2.17 to 2.72), an excess risk
that was partly explained by low levels of physical activity, high body
mass index, poor quality diet and tobacco smoking [9].
In managing chronic pain, although there will be differences in
relation to specific diagnoses, both non-pharmacologic and pharmaco-
logic approaches are generally important. Supported self-management
is a cornerstone of common pain conditions from early in the course
of symptoms through to long-term management. Non-pharmacologic
approaches include physical activity, physical, behavioural and relaxa-
tion therapies and for conditions such as low back pain and fibromyal-
gia, these will be the primary approaches to management [10,11]. A
wide range of analgesics have been used in the management of
chronic pain  however a key recommendation from guidelines of
Research in context
Evidence before this study
We have taken advantage of this large and well-phenotyped UK
cohort. Prior to undertaking the analysis, we conducted a review to
determine the current state of evidence with respect to the preva-
lence of the use of opioids in Europe. The search terms used
included “opioid” and “prevalence” or “prescribing” or “trends” or
“mortality” or “epidemiology” What we found was the evidence
was exclusively around the use of opioids (using routinely collected
data, mainly from primary care). These provided data on patterns
and trends of use (including geographical influences on such).
Added value of this study
This study provides detailed information on the characteristics
and health of people regularly using prescribed opioids. The
data show that use is very strongly related to socio-economic
factors. Indeed a truly startling figure from the manuscript is
that, amongst people who are not able to work because of ill-
health, that 1 in 3 are regularly using opioids.
While use is primarily for chronic pain, the data in this man-
uscript emphasise the poor health of people taking regular
opioids. Almost all still report chronic pain and almost all report
insomnia and few report their health as good. This suggests that
opioids are not effective in the medium and long-term for the
conditions for which they are prescribed.
Finally a multivariable analysis suggests that after health,
socio-economic and lifestyle factors are taken into account, the
regular use of opioids is associated with premature mortality.
This mortality is driven by disease related deaths.
Implications of all the available evidence
This study emphasises the poor health of persons who are taking
opioids regularly. Combining this with other information on the
widespread use of opioids, and the current information that such
persons experience premature mortality, it demonstrates that this
is a major public health issue. There is a need to develop evidence
on effective ways to support people stopping using opioids and
an alternative approach to the management of chronic pain.
2 G.J. Macfarlane et al. / EClinicalMedicine 21 (2020) 100321management is regular review and stopping medications which are
not effective [12].
The World Health Organisation (WHO) analgesic ladder has pro-
vided a framework for the use of analgesics in patients with cancer pain
[13]. The approach recommends that analgesics used should initially be
non-opioids, and then opioids, with the expectation that the strength
and dose of opioids would increase as cancer progressed. Success in the
use of this approach in cancer patients at the end-of-life has led to the
same approach being used for patients with chronic non-cancer pain.
The idea that increasing pain intensity necessitates stronger medicines
in higher doses may hold well for cancer pain where disease burden is
progressing. Using this approach more generally, for non-cancer pain,
has had the consequence of a dramatic increase in the use of prescrip-
tion opioids, most obviously in the United States [14]. It has also made
evident the negative consequences of such widespread use. Reported
pain intensity in chronic non-cancer pain has little to do with tissue
damage and escalation of potent medicines is not justified [15]. There is
good evidence of an increased risk for serious harm (including overdose,
opioid misuse, fractures, myocardial infarction, and markers of sexual
dysfunction). At most they are likely to have only small benefits (in
terms of pain, function and quality of life) in the medium and long-term
[16] - indeed a recent meta-analysis assessed their benefits as similar tonon-opioid analgesics in the management of non-cancer chronic pain,
although the evidence came primarily from low quality studies [16,17].
The purpose of this analysis is therefore to describe the epidemi-
ology of opioid use in Great Britain, the health and quality of life of
people using them and to examine whether their use is associated
with excess mortality.
2. Methods
This study report adheres to STROBE (Strengthening the Reporting
of Observational Studies in Epidemiology) guidelines [18].
UK Biobank recruited around half a million persons aged 4069 years
who were registered with a general practitioner within the National
Health Service (NHS) (see reference [19] for detailed methods). Approxi-
mately 9.2 million invitations were issued, between 200610, to people
living within 25 miles of one of 22 assessment centres across Great Brit-
ain. At the assessment centre, participants responded to questions,
including on demography, social, health and lifestyle factors, by using a
touchscreen. Indices of multiple deprivation (at the small area level) were
used for England, Scotland and Wales to determine the quintile of depri-
vation of their residential area (within the country of residence).
2.1. Pain and medications
In terms of pain, participants were asked “In the last month have you
experienced any of the following that interfered with your usual activi-
ties?” If they answered positively, they were then provided with a list
which included seven individual regional pain sites, or alternatively they
could choose the response “pain all over the body”. Respondents were
asked whether the reported pain had lasted at least three months and
those who reported this for at least one site (or pain all over the body)
were categorised as having “chronic pain”. Participants were asked if
they were taking regular prescription medication and if so, in a nurse-led
interview, were then asked what these were. Information was collected
on regular treatments. It did not include short-termmedications (such as
a course of antibiotics) or prescribed medication that had not been taken.
Interviewers chose the generic or trade name of the treatment from a list.
Information on dose and formulation was not collected. For this analysis,
the full list of treatments was searched for generic or trade names of
opioids, including drugs listed in sub-paragraphs 4.7.1 (Non-Opioid Anal-
gesics and Compound Preparations) and 4.7.2 (Opioid Analgesics) of the
British National Formulary (BNF: https://www.bnf.org/products/bnf-
online). Those that were not commonly prescribed for pain or did not
appear in the BNF sub-paragraphs 4.7.1 and 4.7.2 were not coded as
opioids. Treatments that contained an opioid listed in sub-paragraph
4.7.1 were classed as ‘Combination’ opioids. Other opioids were classed
according to their chemical class (i.e. Codeine, Dihydrocodeine, etc.). Par-
ticipants who took any opioid in the Tramadol, Morphine, Buprenor-
phine, Oxycodone, Fentanyl, or Hydromorphine categories were classed
as taking a strong opioid.
2.2. Vital status and causes of death
For the purposes of collecting information on vital status, partici-
pants were identified on the Office for National Statistics (ONS)
records. ONS collects information on cause of death from civil registra-
tion records. For registered deaths, the underlying cause of death is
derived from the sequence of conditions leading directly to the death
and is recorded on the death certificate. The analysis uses the UK Bio-
bank dataset provided to us in April 2019, which contains death infor-
mation (considered to be complete) up to 31 October 2016.
2.3. Statistical analysis
Descriptive analyses are reported for the use of prescription opioids
by demography and social factors and in relation to pain status. In all
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than non-melanoma skin cancer) were removed, as opioids may have
been prescribed because of cancer pain in such persons. Relationships
with use are described using modified Poisson regression with robust
error variances [20] and are expressed as crude risk ratios (RR) and
adjusted for (as indicated in specific models) age, gender, ethnicity,
region, primary employment status, university degree, deprivation,
income and pain status, namely, the number of body sites in which pain
was reported or pain all over the body and whether pain had lasted
more than three months (i.e. chronic pain).
In examining the relationship between opioid use and subse-
quent mortality, the proportion of persons who died during
follow-up according to their regular use of opioids at the time of
recruitment, is described. Poisson regression models, with robust
estimation of standard errors were used to quantify the relation-
ship expressed as Mortality Risk Ratios (MRR) with adjustment
for pain status, socio-economic factors, and lifestyle factorsTable 1
Regular use of any opioid analgesics by social and demographic factors.
Opioid
Age (years) 4045 48,522
4549 61,043
5054 68,858
5559 79,942
6064 103,71
6570 78,546
Gender Male 206,84
Female 233,78
Ethnicity White 413,50
Mixed 2632 (
Asian or Asian British 9135 (
Black or Black British 7275 (
Chinese 1485 (
Other ethnicity 4111 (
Not known 2477 (
Area of residence South East England 39,283
London 61,745
South West England 38,136
East Midlands 29,809
Yorkshire and Humberside 65,101
West Midlands 39,129
Scotland 31,321
North West England 68,346
Wales 17,784
North East England 49,968
Age completed full time
education (years)
<16 84,320
16 92,270
17 33,972
18 35,749
>18 38,710
Not known 155,60
Deprivation Lowest quintile 90,127
2 88,996
3 88,556
4 87,765
Highest quintile 84,634
Not known 544 (9
Average Household Income (£) Less than 18,000 78,618
18,000 to 30,999 94,514
31,000 to 51,999 100,39
52,000 to 100,000 80,166
>100,000 21,481
Not known 65,444
Primary Employment Employed 264,17
Retired 138,29
Looking after home 12,331
Not working due to health 9963 (
Unemployed 7475 (
Unpaid work 2053 (
Student 1241 (
Not known 5092 (
1 Risk Ratio.
2 Adjusted for age, gender, ethnicity, region, age completed education,shown previously to be potential mediators of the relationship
between chronic pain and mortality.
2.4. Role of the funding source
There were no external sources of funding for the conduct of this
analysis.
3. Results
There were 466,486 persons who were recruited to UK Biobank who
did not report a prior diagnosis of cancer (other than non-melanoma
skin cancer) and these were eligible for the current analysis. Of these,
25,864 reported regular use of opioid medication, which represents 5.5%
of participants. There were striking associations with socio-demographic
factors and use of such medications (see Table 1). Use increased with
age-group and was more common in females than males (6.3% v. 4.6%,Use No: n (%) Opioid Use Yes: n (%) Adjusted RR1,2 (99% CI)
(96.6) 1705 (3.4) 1 [Ref]
(96.1) 2462 (3.9) 1.08 (1.001.17)
(95.4) 3357 (4.7) 1.15 (1.071.24)
(94.4) 4739 (5.6) 1.16 (1.081.24)
1 (93.7) 7020 (6.3) 1.17 (1.081.26)
(92.3) 6581 (7.7) 1.31 (1.201.42)
1 (95.4) 10,057 (4.6) 1 [Ref]
1 (93.7) 15,807 (6.3) 1.43 (1.391.48)
7 (94.4) 24,380 (5.6) 1 [Ref]
94.4) 155 (5.6) 1.07 (0.881.30)
95.3) 452 (4.7) 1.01 (0.891.13)
94.2) 448 (5.8) 1.17 (1.041.31)
98.3) 25 (1.7) 0.45 (0.270.74)
94.3) 246 (5.7) 1.19 (1.011.39)
94.0) 158 (6.0) 1.12 (0.921.37)
(92.2) 1149 (2.8) 1 [Ref]
(96.9) 1975 (3.1) 0.83 (0.760.91)
(95.5) 1803 (4.5) 1.38 (1.251.51)
(94.8) 1634 (5.2) 1.30 (1.181.43)
(94.1) 4056 (5.9) 1.46 (1.341.58)
(93.9) 2564 (6.1) 1.43 (1.311.57)
(93.5) 2178 (6.5) 1.55 (1.421.70)
(93.2) 4973 (6.8) 1.51 (1.391.64)
(92.7) 1407 (7.3) 1.81 (1.642.00)
(92.4) 4125 (7.6) 1.68 (1.551.83)
(89.4) 10,033 (10.6) 1.24 (1.191.29)
(93.9) 6041 (6.1) 1 [Ref]
(95.1) 1741 (4.9) 0.90 (0.840.96)
(96.1) 1440 (3.9) 0.81 (0.750.87)
(96.0) 1619 (4.0) 0.80 (0.750.86)
1 (96.9) 4990 (3.1) 0.71 (0.680.75)
(96.4) 3353 (3.6) 1 [Ref]
(95.8) 3899 (4.2) 1.10 (1.041.16)
(95.1) 4563 (4.9) 1.22 (1.161.29)
(94.2) 5420 (5.8) 1.41 (1.341.49)
(90.8) 8597 (9.2) 1.75 (1.651.84)
4.4) 32 (95.6) 1.45 (0.932.25)
(88.9) 9820 (11.1) 1 [Ref]
(94.7) 5322 (5.3) 0.81 (0.780.85)
9 (96.7) 3447 (3.3) 0.69 (0.660.73)
(98.0) 1616 (2.0) 0.53 (0.490.57)
(98.9) 240 (1.1) 0.34 (0.290.40)
(92.4) 5419 (7.6) 0.89 (0.850.93)
1 (97.1) 7952 (2.9) 1 [Ref]
6 (92.4) 11,346 (7.6) 1.76 (1.671.85)
(94.9) 666 (5.1) 1.43 (1.291.58)
66.3) 5069 (33.7) 6.62 (6.306.94)
95.1) 383 (4.9) 1.23 (1.071.40)
95.5) 97 (4.5) 1.33 (1.031.72)
96.2) 49 (3.8) 1.11 (0.771.60)
94.4) 302 (5.6) 1.53 (1.311.78)
primary employment status, deprivation, and income.
Table 2
Specific opioids reported by participants as being taking regularly?
Opioid drug/preparation- N %
Weak opioids Combined1 17,065 3.7
Codeine 2304 0.5
Dihydrocodeine 1617 0.4
Meptazinol 67 0.0
Pethidine 24 0.0
Dextropropoxyphene 1 0.0
Strong opioids Tramadol 5346 1.2
Morphine 508 0.1
Buprenorphine 349 0.1
Oxycodone 220 0.0
Fentanyl 233 0.0
Hydromorphone 7 0.0
1 Combined = preparations listed in the BNF Sub-paragraph
‘Non-Opioid Analgesics and Compound Prep’, e.g. co-codamol, co-
codaprin, etc.
4 G.J. Macfarlane et al. / EClinicalMedicine 21 (2020) 100321adjusted for demographic, employment status, education level and eco-
nomic factors RR 1.43 99%CI (1.391.48)). There was little variation by
ethnic group except that use of opioids was uncommon amongst per-
sons of Chinese origin (1.7%, adjusted RR 0.45 99% CI (0.270.74) in com-
parison to persons identifying as “white”). There were marked
differences between areas of residence, from 2.8% in South-East England
to 7.6% in the North-East of England (adjusted RR 1.75 99% CI
(1.611.91)). The highest rates of reported use were found in persons
with low household income (11.1% in those reporting annual household
income of less than £18,000), those who left school before 16 years
(10.6%) and who lived in areas with the highest levels of deprivation
(9.2%). Amongst the 15,032 people who reported that they could not
work because of ill-health 33.7% were regularly taking opioids. A total of
6419 persons (1.3%) reported regular use of strong opioids. Use of strong
opioids also showed a strong relationship with area of residence, high
levels of deprivation, low income and not working due to ill-health (sup-
plementary table).
The most common opioid reported was combined preparations,
and thereafter codeine and dihydrocodeine. The most common
strong opioids were tramadol then morphine and buprenorphine
(Table 2). Of persons reporting taking regular opioids, 23,731 (5.1%)
reported using a single opioid, 1976 (0.4%) were taking two opioids
and 157 (0.03%) were taking 3 or more.
The vastmajority (87.3%) of persons regularly taking opioids reported
chronic pain: the likelihood of taking opioids increased with greater
number of reported pain sites from 3.8% in those reporting one site up to
30.7% in those who reported 7 sites or “pain all over the body” RR (16.66
99% CI (15.4217.99)) adjusted for age, gender, demographic factors,
socio-economic factors and primary employment (Table 3). When the
relationship was examined by the reporting of pain at individual sites,
with adjustment as above plus total number of pain sites reported, allTable 3
Regular use of opioid analgesics in relation to pain reporting.
Opioid Use No, n (%
Chronic pain No 259,318 (98.8)
Yes 179,367 (88.9)
Number of pain sites 0 181,619 (99.0)
1 123,042 (96.2)
2 71,910 (92.9)
3 35,369 (87.1)
4 14,521 (81.0)
5 5044 (74.3)
6 1387 (69.7)
7 or all over 5793 (69.3)
1 Risk Ratio.
2 Adjusted for age, gender, ethnicity, region, primary em
income.individual pain sites, with the exception of facial pain, were associated
with an excess risk of regular opioid use (data not shown). The associa-
tions shown in Table 1 were not explained when adjusted for pain status
(chronic pain and number of pain sites) although some were attenuated,
most noticeably female gender (RR 1.23 95% CI (1.191.26)) and
amongst those living in areas with the highest level of deprivation (RR
1.50 95% CI (1.421.58)).
The relationship of opioid use with health, lifestyle factors and life
events is detailed in Table 4. After adjustment for potential confound-
ing factors, persons rating their health as “poor” were considerably
more likely to regularly take opioids compared to those rating their
health as “excellent” (RR 5.44 99% CI (4.896.05) as were those
reporting only minimal physical activity. Those reporting poor qual-
ity sleep (both less and more than the average of 78 h, as well as
usually suffering from insomnia (RR 1.56 99% CI (1.481.64)) and
poorer mental health (i.e. reported having consulted a GP for “anxi-
ety, nerves or depression” (RR 1.29 99% CI (1.251.34)) were also
more likely to report regular opioid use. There was a “dose-risk” rela-
tionship between the number of adverse events in last two years and
likelihood of using opioids such that those reporting at least four
such events were over 50% more likely to be taking opioids regularly
(RR 1.55 99% CI (1.361.76)).
3.1. The relationship between opioid consumption and mortality
16,432 persons died during follow-up. Of participants who at
recruitment were not regularly taking opioids, 3.3% died during fol-
low-up (428 per 100 000 person-years (py)); in comparison 6.9% of
those taking weak opioids (892 per 100 000 py) and 9.1% of those tak-
ing strong opioids died (1194 per 100 000py) (age and sex adjusted
Mortality Risk Ratio (MRR) 1.86, 99% CI (1.73, 2.00) and 2.59 99% CI
(2.34, 2.88) respectively) (Table 5). Chronic pain was also related to
excess mortality; for example, of persons who at recruitment
reported “pain all over their body” or pain at all seven regional sites
6.8% died during follow-up in comparison to 3.2% of persons with no
pain (MRR 2.29, 99% CI 2.06, 2.56). In addition, lifestyle factors
(physical activity, BMI, diet (including alcohol consumption and
cigarette smoking), socio-economic factors (years of education,
income and level of deprivation of area of residence) and morbid-
ities were also importantly linked with risk of mortality. When
adjustment was made for all these factors, there remained an
association between regular opioid use at recruitment and risk of
death over the following 610 years (MRR weak opioids 1.18 99%
CI (1.06, 1.33)), strong opioids (MRR 1.20 99% CI (1.01, 1.43)). Of
the deaths which occurred amongst persons using regular opioids
39% were cancer deaths (in comparison to 53% in non-opioid
users), 28% were cardiovascular (v. 23%), 11% were respiratory (v.
6%), 18% were other diseases (v. 13%) and 3% were from external
causes (v. 4%).) Opioid Use Yes, n (%) Adjusted RR1,2 (99% CI)
3271 (1.2) 1 [Reference]
22,460 (11.1) 6.69 (6.387.02)
1797 (1.0) 1 [Reference}
4925 (3.8) 3.72 (3.474.00)
5468 (7.1) 6.27 (5.856.72)
5225 (12.9) 10.14 (9.4610.87)
3396 (19.0) 13.32 (12.3814.33)
1748 (25.7) 15.84 (14.5917.20)
604 (30.3) 17.60 (15.8119.60)
2568 (30.7) 16.66 (15.4217.99)
ployment, age completed education, deprivation, and
Table 4
Regular use of any opioid analgesic in relation to health status.
Opioid Use No, n (%) Opioid Use Yes, n(%) Adjusted RR1
Hours of sleep 4 or less 4010 (77.5) 1163 (22.5) 1.55 (1.451.67)
5 or 6 101,161 (92.7) 8024 (7.4) 1.23 (1.191.27)
7 or 8 300,512 (95.9) 12,923 (4.1) 1 [Reference]
9 or 10 30,068 (91.5) 2794 (8.5) 1.21 (1.161.28)
11 or more 1492 (77.7) 428 (22.3) 1.41 (1.271.57)
Insomnia Never/rarely 110,911 (97.4) 2926 (2.6) 1 [Reference]
Sometimes 212,122 (95.5) 10,105 (4.5) 1.21 (1.151.27)
Usually 116,227 (90.1) 12,749 (9.9) 1.56 (1.481.64)
Overall
activity
Minimal 84,354 (91.9) 7407 (8.1) 1 [Reference]
Low 74,214 (95.7) 3368 (4.3) 0.74 (0.700.77)
Adequate 120,525 (95.3) 5929 (4.7) 0.74 (0.710.77)
High 125,585 (96.3) 4803 (3.7) 0.67 (0.640.70)
Overall health
rating
Excellent 77,541 (99.1) 732 (0.9) 1 [Reference]
Good 261,428 (96.9) 8327 (3.1) 1.98 (1.802.19)
Fair 84,888 (88.9) 10,598 (11.1) 3.92 (3.544.33)
Poor 13,908 (70.2) 5908 (29.8) 5.44 (4.896.05)
Seen doctor for anxiety/ nerves/
depression
No 293,787 (96.1) 11,907 (3.9) 1 [Reference]
Yes 142,478 (91.3) 13,598 (8.7) 1.29 (1.251.34)
Adverse events in last 2 years
(illness, injury,
assault, bereavement,
divorce, financial difficulty)
0 245,686 (95.8) 10,801 (4.2) 1 [Reference]
1 139,738 (93.8) 9301 (6.2) 1.16 (1.121.20)
2 39,180 (91.4) 3693 (8.6) 1.26 (1.201.31)
3 7710 (87.0) 1147 (13.0) 1.37 (1.271.47)
4 or more 1201 (80.3) 295 (19.7) 1.55 (1.361.76)
1 Adjusted for age, gender, ethnicity, region, primary employment, age completed education, deprivation, income, any
chronic pain, and number of pain sites.
Table 5
Predictors of death during follow-up period.
Recruitment characteristic Death during follow-up MRR1 (99% CI) MRR2 (99% CI)
No: N (%) Yes: N (%)
Regular Opioid use None 426,534 (96.7%) 14,513 (3.3%) 1 [Reference] 1 [Reference]
Weak 18,136 (93.1%) 1336 (6.9%) 1.86 (1.73, 2.00) 1.18 (1.06, 1.33)
Strong 5853 (90.9%) 583 (9.1%) 2.59 (2.34, 2.88) 1.20 (1.01, 1.43)
Chronic Pain No 254,379 (96.8%) 8417 (3.2%) 1 [Reference] 1 [Reference]
Yes 194,172 (96.1%) 7900 (3.9%) 1.22 (1.17, 1.27) 0.85 (0.78, 0.93)
Number of pain sites 0 179,617 (96.8%) 6004 (3.2%) 1 [Reference] 1 [Reference]
1 123,741 (96.6%) 4334 (3.4%) 1.06 (1.01, 1.11) 1.07 (0.97, 1.17)
2 74,684 (96.4%) 2794 (3.6%) 1.17 (1.11, 1.24) 1.05 (0.94, 1.17)
3 38,990 (95.9%) 1665 (4.1%) 1.36 (1.27, 1.46) 1.09 (0.96, 1.25)
4 17,245 (96.1%) 700 (3.9%) 1.35 (1.23, 1.50) 0.94 (0.79, 1.12)
5 6517 (95.8%) 286 (4.2%) 1.58 (1.35, 1.83) 0.85 (0.66, 1.09)
6 1913 (96.0%) 80 (4.0%) 1.65 (1.25, 2.19) 1.07 (0.73, 1.56)
7 or all over 7803 (93.2%) 567 (6.8%) 2.29 (2.06, 2.56) 1.19 (0.98, 1.45)
Age Category (years) 4045 49,892 (99.2%) 396 (0.8%) 1 [Reference] 1 [Reference]
4549 62,760 (98.7%) 796 (1.3%) 1.61 (1.37, 1.88) 1.71 (1.33, 2.20)
5054 70,924 (98.1%) 1361 (1.9%) 2.43 (2.10, 2.81) 2.33 (1.84, 2.95)
5559 82,301 (97.1%) 2464 (2.9%) 3.73 (3.25, 4.28) 3.41 (2.72, 4.28)
6064 105,927 (95.6%) 4905 (4.4%) 5.63 (4.92, 6.43) 4.64 (3.72, 5.80)
6569 78,706 (92.4%) 6508 (7.6%) 9.50 (8.32, 10.85) 6.89 (5.51, 8.62)
Gender Male 206,662 (95.2%) 10,364 (4.8%) 1 [Reference] 1 [Reference]
Female 243,848 (97.6%) 6066 (2.4%) 0.53 (0.51, 0.55) 0.51 (0.48, 0.55)
Body Mass Index (kgm2) Underweight (< 18.5) 2208 (93.0%) 166 (7.0%) 2.83 (2.34, 3.43) 1.76 (1.31, 2.38)
Normal (18.524.9) 146,451 (97.1%) 4308 (2.9%) 1 [Reference] 1 [Reference]
Overweight (25.029.9) 190,832 (96.6%) 6674 (3.4%) 0.96 (0.91, 1.01) 0.87 (0.81, 0.94)
Obese (30.034.9) 77,950 (95.9%) 3302 (4.1%) 1.17 (1.10, 1.24) 0.94 (0.86, 1.02)
Obese (35.039.9) 22,033 (95.2%) 1116 (4.8%) 1.55 (1.42, 1.68) 1.05 (0.93, 1.20)
Obese (40) 11,036 (92.7%) 864 (7.3%) 2.56 (2.34, 2.81) 1.45 (1.24, 1.69)
Physical Activity (walking: mins/week) 0 9251 (93.7%) 622 (6.3%) 1.90 (1.71, 2.11) 1.22 (1.05, 1.40)
1100 101,757 (96.6%) 3594 (3.4%) 1 [Reference] 1 [Reference]
101210 115,233 (96.7%) 3939 (3.3%) 0.91 (0.86, 0.96) 0.97 (0.89, 1.05)
211420 90,340 (96.8%) 2983 (3.2%) 0.87 (0.82, 0.93) 0.92 (0.84, 1.01)
>420 75,450 (96.8%) 2502 (3.2%) 0.90 (0.84, 0.96) 0.87 (0.79, 0.96)
Moderate Physical Activity (mins/week) 0 54,253 (95.3%) 2691 (4.7%) 1.58 (1.47, 1.69) 1.11 (1.005, 1.23)
160 93,837 (97.1%) 2787 (2.9%) 1 [Reference] 1 [Reference]
61150 79,046 (97.0%) 2446 (3.0%) 0.98 (0.91, 1.05) 0.98 (0.89, 1.09)
151360 79,792 (96.9%) 2564 (3.1%) 0.95 (0.88, 1.01) 1.01 (0.91, 1.11)
>360 79,205 (96.5%) 2908 (3.5%) 0.99 (0.93, 1.06) 1.06 (0.95, 1.17)
Vigorous Physical Activity (mins/week) 0 158,097 (95.6%) 7323 (4.4%) 1 [Reference] 1 [Reference]
140 71,056 (91.2%) 2053 (2.8%) 0.65 (0.61, 0.69) 0.87 (0.79, 0.95)
4190 62,605 (97.4%) 1689 (2.6%) 0.64 (0.60, 0.69) 0.88 (0.79, 0.97)
91180 57,870 (97.5%) 1536 (2.5%) 0.63 (0.59, 0.68) 0.85 (0.76, 0.95)
(continued)
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Table 5 (Continued)
Recruitment characteristic Death during follow-up MRR1 (99% CI) MRR2 (99% CI)
>180 51,434 (97.2%) 1486 (2.8%) 0.65 (0.60, 0.69) 0.84 (0.75, 0.93)
Physical activity (stairs times/day) 0 38,711 (94.1%) 2425 (5.9%) 1.12 (1.05, 1.20) 1.02 (0.93, 1.11)
15 89,429 (95.7%) 3984 (4.3%) 1 [Reference] 1 [Reference]
610 161,615 (96.9%) 5114 (3.1%) 0.71 (0.67, 0.75) 0.85 (0.79, 0.92)
1115 82,692 (97.3%) 2301 (2.7%) 0.63 (0.59, 0.68) 0.82 (0.75, 0.91)
1620 38,451 (97.3%) 1058 (2.7%) 0.63 (0.57, 0.68) 0.80 (0.70, 0.92)
>20 31,363 (97.3%) 876 (2.7%) 0.68 (0.62, 0.75) 0.81 (0.69, 0.94)
Diet (Fruit and Vegetable Consumption)
Alcohol Consumption
Lowest consumption 101,510 (95.9%) 4393 (4.1%) 1 [Reference] 1 [Reference]
Quintile 2 91,076 (96.7%) 3119 (3.3%) 0.77 (0.73, 0.82) 0.91 (0.84, 0.99)
Quintile 3 40,106 (96.8%) 1343 (3.2%) 0.75 (0.69, 0.81) 0.92 (0.82, 1.02)
Quintile 4 80,665 (96.8%) 2641 (3.2%) 0.73 (0.68, 0.77) 0.91 (0.83, 0.99)
Highest Consumption 64,907 (96.7%) 2205 (3.3%) 0.75 (0.70, 0.80) 0.90 (0.82, 0.99)
(almost) daily 90,705 (95.9%) 3843 (4.1%) 1 [Reference] 1 [Reference]
34 times/week 104,889 (97.1%) 3127 (2.9%) 0.82 (0.78, 0.88) 0.90 (0.82, 0.98)
12 times/week 116,686 (96.9%) 3715 (3.1%) 0.94 (0.89, 0.99) 0.91 (0.83, 0.99)
<1 time/week 101,408 (96.5%) 3698 (3.5%) 1.15 (1.08, 1.22) 0.95 (0.86, 1.04)
Never 35,463 (94.7%) 1966 (5.3%) 1.59 (1.48, 1.70) 1.23 (1.10, 1.37)
Cigarette Smoking Current smoker 45,818 (92.8%) 3546 (7.2%) 3.12 (2.96, 3.29) 2.44 (2.24, 2.65)
Ex-regular 101,104 (95.1%) 5253 (4.9%) 1.59 (1.51, 1.66) 1.46 (1.35, 1.57)
Ex-occasional 51,343 (97.1%) 1536 (2.9%) 1.09 (1.02, 1.17) 1.14 (1.02, 1.27)
Never 249,750 (97.7%) 5942 (2.3%) 1 [Reference] 1 [Reference]
Morbidity count3 0 120,558 (98.0%) 2416 (2.0%) 1 [Reference] 1 [Reference]
1 122,894 (97.4%) 3285 (2.6%) 1.15 (1.07, 1.23) 1.07 (0.97, 1.19)
2 88,310 (96.4%) 3299 (3.6%) 1.40 (1.31, 1.50) 1.22 (1.10, 1.36)
3 54,451 (95.2%) 2743 (4.8%) 1.72 (1.60, 1.85) 1.47 (1.32, 1.64)
4 30,396 (94.4%) 1819 (5.4%) 1.93 (1.78, 2.09) 1.51 (1.34, 1.71)
5 16,020 (93.2%) 1169 (6.8%) 2.27 (2.08, 2.49) 1.65 (1.43, 1.90)
6 8481 (82.6%) 680 (7.4%) 2.49 (2.23, 2.78) 1.70 (1.43, 2.01)
7 4437 (91.3%) 421 (8.7%) 2.91 (2.56, 3.32) 1.83 (1.49, 2.25)
8 2257 (90.6%) 233 (9.4%) 3.15 (2.67, 3.73) 2.22 (1.74, 2.84)
9 1259 (89.9%) 142 (10.1%) 3.63 (2.94, 4.48) 2.59 (1.92, 3.49)
>=10 1147 (86.6%) 223 (13.4%) 4.77 (4.04, 5.63) 2.95 (2.27, 3.82)
Age completed full time education (years) <16 88,210 (93.8%) 5824 (6.2%) 1 [Reference] 1 [Reference]
16 95,204 (96.8%) 3202 (3.3%) 0.78 (0.74, 0.83) 0.93 (0.86, 0.999)
17 34,717 (97.1%) 1030 (2.9%) 0.69 (0.63, 0.75) 0.88 (0.78, 0.98)
18 36,264 (97.4%) 953 (2.6%) 0.67 (0.62, 0.74) 0.95 (0.84, 1.06)
>18 39,102 (96.9%) 1264 (3.1%) 0.70 (0.65, 0.76) 1.02 (0.92, 1.13)
Average household income (£) Less than 18,000 83,059 (93.8%) 5480 (6.2%) 1 [Reference] 1 [Reference]
18,000 to 30,999 96,144 (96.2%) 3788 (3.8%) 0.66 (0.62, 0.69) 0.85 (0.79, 0.92)
31,000 to 51,999 101,608 (97.8%) 2339 (2.3%) 0.47 (0.44, 0.51) 0.68 (0.61, 0.75)
52,000 to 100,000 80,513 (98.4%) 1334 (1.6%) 0.39 (0.36, 0.43) 0.61 (0.53, 0.70)
>100,000 21,443 (98.7%) 293 (1.4%) 0.33 (0.29, 0.39) 0.51 (0.37, 0.71)
Do not know 18,475 (94.8%) 1011 (5.2%) 1.02 (0.94, 1.11) 1.03 (0.89, 1.19)
Prefer not to answer 44,092 (96.2%) 1752 (3.8%) 0.69 (0.64, 0.74) 0.79 (0.70, 0.88)
Deprivation Lowest quintile 90,849 (97.1%) 2727 (2.9%) 1 [Reference] 1 [Reference]
2 90,161 (97.0%) 2826 (3.0%) 1.04 (0.97, 1.12) 0.93 (0.84, 1.03)
3 90,242 (96.8%) 2962 (3.2%) 1.12 (1.05, 1.20) 1.00 (0.91, 1.11)
4 89,972 (96.5%) 3302 (3.5%) 1.32 (1.24, 1.41) 1.08 (0.98, 1.19)
Highest quintile 88,726 (95.1%) 4596 (4.9%) 1.92 (1.81, 2.04) 1.22 (1.11, 1.35)
Seen doctor for anxiety/ nerves/depression No 295,416 (96.6%) 10,519 (3.4%) 1 [Reference] 1 [Reference]
Yes 150,588 (96.4%) 5695 (3.6%) 1.26 (1.21, 1.31) 0.98 (0.92, 1.04)
1 Mortality Risk Ratio adjusted for age and gender.
2 Fully adjusted mortality risk ratio  i.e. adjusted for all factors in table.
3 Self-reported illness (non-cancer) at baseline.
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Regular use of opioids in UK Biobank participants was very
strongly related to socio-economic factors: around 1 in 10 people
with the lowest level of incomes, those living in areas with the high-
est levels of deprivation and who left education at a young age,
reported regular opioid use, while this rose to 1 in 3 of persons
reporting that they were unable to work due to ill-health. After
adjusting for pain status and socio-economic factors, regularly taking
opioids was associated with poorer physical and mental health and
quality of life (such as sleep quality) and was associated with
increased risk of death, even after additionally taking into account
lifestyle factors and other morbidities. The increased risk of death
was not primarily as a result of non-disease deaths.
UK Biobank is a very large study, but the proportion of people
invited, who agreed to take part was low (just over 5%). There isevidence that those taking part are healthier than the general popula-
tion: specifically they are less likely to be obese, to smoke, and to drink
alcohol on a daily basis and they have fewer self-reported health condi-
tions. Rates of all-cause mortality have been shown at age 7074 years
to be 46% and 56% lower in men and women, respectively than the
wider population [21]. The valid assessment, however, of an exposure
outcome relationship does not rely on the population being representa-
tive of the underlying population aged 4069 years who were eligible
to take part. Thus our estimate of the use of opioids in Great Britain,
although high, is likely to be an underestimate. We have, however, pre-
viously compared the prevalence of chronic pain in UK Biobank with
other epidemiological studies whichmeasured chronic pain, and shown,
for example, that the estimates of prevalence of chronic pain and
regional pain using UK Biobank were within 2% of the National Child
Development Study [22]. The secondmethodological issue in examining
factors associated with the use of opioids is the strong relationship with
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cause of chronic pain and so we have adjusted for the presence of
chronic pain and the number of pain sites. However, we do not have a
measure of the severity of chronic pain and therefore there may be
residual confounding e.g. if more severe pain was linked to greater
interference with sleep and a greater likelihood of opioid use. There is
also limited information on opioids in this study. We are not aware of
the dose of opioids or for how long they have been used at the time of
recruitment, nor of changes over follow-up; neither is information avail-
able on non-prescription (“over the counter”) opioid use. Thus, for
example, we cannot examine whether the relationship with poor physi-
cal andmental health, for example, is related to dose.
The factors associated with regular opioid use in this study (after
adjustment for pain status) namely depression, anxiety and insomnia are
recognised adverse effects of opioid use [23]. The results, in relation to
mortality, do not necessarily mean that opioids themselves are leading to
an increased risk of death. There could be unmeasured confounders of
the relationship  if so, these factors need to be relatively common, be
related to opioid use and be risk factors for premature death. Specifically,
there could be confounding by indication, namely that persons are
receiving opioids for unmeasured aspects of their clinical conditionwhich
are themselves related to an increased risk of death. Such a scenario may
explain some or all of the association observed. The association of opioid
use and misuse with premature death is well-documented, although that
typically has been related to non-disease related deaths (e.g. Reference
[24]). Non-disease related deaths were relatively uncommon in this anal-
ysis and not responsible for the excess mortality. Long term opioid use
has been shown to relate to an increased risk of death by a number of
potential mechanisms including the very common finding of disruption
of nocturnal respiratory control leading to both respiratory and cardio-
vascular morbidity [25,26]. Studies of opioids and cancer have primarily
focussed on the use of opioids during cancer surgery and subsequent sur-
vival. Two studies have reported a higher recurrence rate of breast and
prostate cancers [27,28] although the only study of opioid use after sur-
gery found no increased risk of recurrence in breast cancer patients [29].
A recent study of approximately 90 000 persons, using electronic records
within UK general practice, has however linked the initial prescription of
tramadol, in patients over 50 years with osteoarthritis, to higher mortal-
ity rates over the subsequent year (hazard ratio 1.71 95% CI (1.41,2.07) v.
patients receiving nonsteroidal anti-inflammatory drugs) [30].
We have previously published data from Scotland, using record
linkage, which demonstrated a sizeable increase in the prescriptions
for opioids across the ten-year period from 2003 [31]. This study
showed that 18% of the population in Scotland had been prescribed an
opioid in the past year, much higher than the proportion reported in
the current study ( in which 6.5% persons from Scotland reported regu-
lar opioid use). There are likely to be at least three reasons for the dis-
crepancy: the current study is based on “regular use of medication”
while the previous study was based on a record of at least one pre-
scription; the selection effects in participating; and that we have
excluded persons with a cancer diagnosis in this analysis. The large
variations in regular use of opioids across GB in this study, replicate a
recent study from England [32] which found that high prescribing was
related to deprivation, large primary care list size and rurality. A fur-
ther study, from one area of Scotland, which analysed prescribing of
analgesics between 19952010 also found that persons living in
deprived areas (as well as those receiving large numbers of non- anal-
gesic drugs) were most likely to be prescribed a strong opioid [33].
It is no surprise that users of opioids are likely to report chronic
pain: we assume this is the reason for opioid use. However the data
show high levels of continuing poor health among those using
opioids including inability to work, poor physical and mental health,
quality of life and poor sleep These findings accord with previous
findings from a large epidemiological study in Denmark which noted
that “opioid treatment of long-term/chronic non-cancer pain does not
seem to fulfil any of the key outcome opioid treatment goals” [34].Much evidence on the so-called “opioid epidemic” has come from
the United States where the Center for Disease Control (CDC) has devel-
oped a guideline to improve the way opioids are prescribed to “ensure
patients have access to safer, more effective chronic pain treatment
while reducing the number of people who misuse or overdose from
these drugs” [35] and the Scottish Intercollegiate Guidelines Network
(SIGN) have recently revised their guideline on managing chronic pain
in order to update recommendations on opioids [12]. The latter suggest
early review of patients newly prescribed opioid medication and at
least annual review thereafter. This manuscript has demonstrated high
levels of regular opioid use amongst people in the UK, particularly
those in lower socio-economic groups. Amongst users, chronic pain is
still common, and a large proportion report poor physical and mental
health, while the majority report sleep problems. This study adds to
current evidence in showing that regular users also experience an
increased risk of death (but not primarily as a result of non-disease
deaths). It emphasises the need to take into account such potential
harms and lack of benefit of regular opioid use in considering the long-
termmanagement of patients with pain.
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